{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:28:12Z","timestamp":1792621692009,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s13555-026-01900-0","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:27:48Z","timestamp":1790872068000},"page":"5175-5193","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Window of Opportunity and Predictors of Sustained Remission in Patients with Hidradenitis Suppurativa Treated with Adalimumab: A 540-Patient Cohort Study"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6507-0534","authenticated-orcid":false,"given":"Eva","family":"Vilarrasa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Garbayo-Salmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emili","family":"Masferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Corral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Bassas-Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Luque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Fuertes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Fornons-Servent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Martin-Ezquerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael S.","family":"Aguayo-Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Ceravalls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"G\u00f3mez-Tom\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Mollet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Matas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignasi","family":"Gich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Roman\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"issue":"1","key":"1900_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0149-1","volume":"6","author":"R Sabat","year":"2020","unstructured":"Sabat R, Jemec GBE, Matusiak \u0141, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6(1):18. https:\/\/doi.org\/10.1038\/s41572-020-0149-1.","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"1900_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cells10082094","volume":"10","author":"E Scala","year":"2021","unstructured":"Scala E, Cacciapuoti S, Garzorz-Stark N, et al. Hidradenitis suppurativa: where we are and where we are going. Cells. 2021;10(8):2094. https:\/\/doi.org\/10.3390\/cells10082094.","journal-title":"Cells"},{"issue":"9","key":"1900_CR3","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.ad.2015.06.004","volume":"106","author":"A Martorell","year":"2015","unstructured":"Martorell A, Garc\u00eda-Mart\u00ednez FJ, Jim\u00e9nez-Gallo D, et al. An update on hidradenitis suppurativa (part I): epidemiology, clinical aspects, and definition of disease severity. Actas Dermosifiliogr. 2015;106(9):703\u201315. https:\/\/doi.org\/10.1016\/j.ad.2015.06.004. (in English and Spanish).","journal-title":"Actas Dermosifiliogr"},{"issue":"3","key":"1900_CR4","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.jaad.2012.07.027","volume":"68","author":"I Cosmatos","year":"2013","unstructured":"Cosmatos I, Matcho A, Weinstein R, Montgomery MO, Stang P. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol. 2013;68(3):412\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2012.07.027.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1900_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/jid.2012.255","volume":"133","author":"BG Vazquez","year":"2013","unstructured":"Vazquez BG, Alikhan A, Weaver AL, Wetter DA, Davis MD. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol. 2013;133(1):97\u2013103. https:\/\/doi.org\/10.1038\/jid.2012.255.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"1900_CR6","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.jaci.2022.02.003","volume":"149","author":"KR van Straalen","year":"2022","unstructured":"van Straalen KR, Prens EP, Gudjonsson JE. Insights into hidradenitis suppurativa. J Allergy Clin Immunol. 2022;149(4):1150\u201361. https:\/\/doi.org\/10.1016\/j.jaci.2022.02.003.","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"1900_CR7","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/exd.14214","volume":"29","author":"CC Zouboulis","year":"2020","unstructured":"Zouboulis CC, Benhadou F, Byrd AS, et al. What causes hidradenitis suppurativa?\u201415 years after. Exp Dermatol. 2020;29(12):1154\u201370. https:\/\/doi.org\/10.1111\/exd.14214.","journal-title":"Exp Dermatol"},{"issue":"8","key":"1900_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10082039","volume":"10","author":"C Moltrasio","year":"2022","unstructured":"Moltrasio C, Tricarico PM, Romagnuolo M, Marzano AV, Crovella S. Hidradenitis suppurativa: a perspective on genetic factors involved in the disease. Biomedicines. 2022;10(8):2039. https:\/\/doi.org\/10.3390\/biomedicines10082039.","journal-title":"Biomedicines"},{"issue":"9","key":"1900_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/life13091895","volume":"13","author":"A Nowak-Liduk","year":"2023","unstructured":"Nowak-Liduk A, Kitala D, Ocha\u0142a-Gierek G, et al. Hidradenitis suppurativa: an interdisciplinary problem in dermatology, gynecology, and surgery-pathogenesis, comorbidities, and current treatments. Life. 2023;13(9):1895. https:\/\/doi.org\/10.3390\/life13091895.","journal-title":"Life"},{"issue":"1","key":"1900_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1159\/000503605","volume":"237","author":"AJ Hendricks","year":"2021","unstructured":"Hendricks AJ, Hsiao JL, Lowes MA, Shi VY. A comparison of international management guidelines for hidradenitis suppurativa. Dermatology. 2021;237(1):81\u201396. https:\/\/doi.org\/10.1159\/000503605.","journal-title":"Dermatology"},{"issue":"9","key":"1900_CR11","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1111\/ijd.16115","volume":"61","author":"M Lewandowski","year":"2022","unstructured":"Lewandowski M, \u015awierczewska Z, Bara\u0144ska-Rybak W. Hidradenitis suppurativa: a review of current treatment options. Int J Dermatol. 2022;61(9):1152\u201364. https:\/\/doi.org\/10.1111\/ijd.16115.","journal-title":"Int J Dermatol"},{"key":"1900_CR12","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.2147\/CCID.S301794","volume":"16","author":"CL Snyder","year":"2023","unstructured":"Snyder CL, Chen SX, Porter ML. Obstacles to early diagnosis and treatment of hidradenitis suppurativa: current perspectives on improving clinical management. Clin Cosmet Investig Dermatol. 2023;16:1833\u201341. https:\/\/doi.org\/10.2147\/CCID.S301794.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"6","key":"1900_CR13","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1093\/bjd\/ljae098","volume":"190","author":"CC Zouboulis","year":"2024","unstructured":"Zouboulis CC, Passeron T, Pariser D, et al. Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials. Br J Dermatol. 2024;190(6):836\u201345.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1900_CR14","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/jdv.20472","volume":"39","author":"CC Zouboulis","year":"2025","unstructured":"Zouboulis CC, Bechara FG, Benhadou F, et al. European S2k guidelines for hidradenitis suppurativa\/acne inversa part 2: treatment. J Eur Acad Dermatol Venereol. 2025;39(5):899\u2013941. https:\/\/doi.org\/10.1111\/jdv.20472.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1900_CR15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/BTT.S199862","volume":"13","author":"SYD Lim","year":"2019","unstructured":"Lim SYD, Oon HH. Systematic review of immunomodulatory therapies for hidradenitis suppurativa. Biologics. 2019;13:53\u201378. https:\/\/doi.org\/10.2147\/BTT.S199862.","journal-title":"Biologics"},{"issue":"5","key":"1900_CR16","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/1744666X.2023.2298356","volume":"20","author":"CA Maronese","year":"2024","unstructured":"Maronese CA, Moltrasio C, Genovese G, Marzano AV. Biologics for hidradenitis suppurativa: evolution of the treatment paradigm. Expert Rev Clin Immunol. 2024;20(5):525\u201345. https:\/\/doi.org\/10.1080\/1744666X.2023.2298356.","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"1900_CR17","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504370.","journal-title":"N Engl J Med"},{"issue":"1","key":"1900_CR18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/jdv.20044","volume":"39","author":"P Garbayo-Salmons","year":"2025","unstructured":"Garbayo-Salmons P, Vilarrasa E, Bassas-Vila J, et al. Real-world adalimumab survival and discontinuation factors in hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2025;39(1):221\u20139. https:\/\/doi.org\/10.1111\/jdv.20044.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5-6","key":"1900_CR19","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1159\/000539264","volume":"240","author":"A Offidani","year":"2024","unstructured":"Offidani A, Marzano AV, Peris K, et al. Guidelines how to integrate surgery and targeted therapy with biologics for the treatment of hidradenitis suppurativa: Delphi consensus statements from an Italian expert panel. Dermatology. 2024;240(5\u20136):885\u201396. https:\/\/doi.org\/10.1159\/000539264.","journal-title":"Dermatology"},{"issue":"11","key":"1900_CR20","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1001\/jamasurg.2021.3655","volume":"156","author":"FG Bechara","year":"2021","unstructured":"Bechara FG, Podda M, Prens EP, et al. Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: the SHARPS randomized clinical trial. JAMA Surg. 2021;156(11):1001\u20139. https:\/\/doi.org\/10.1001\/jamasurg.2021.3655.","journal-title":"JAMA Surg"},{"issue":"4","key":"1900_CR21","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jaad.2023.04.034","volume":"89","author":"P Aarts","year":"2023","unstructured":"Aarts P, van Huijstee JC, van der Zee HH, van Doorn MBA, van Straalen KR, Prens EP. Adalimumab in conjunction with surgery compared with adalimumab monotherapy for hidradenitis suppurativa: a randomized controlled trial in a real-world setting. J Am Acad Dermatol. 2023;89(4):677\u201384. https:\/\/doi.org\/10.1016\/j.jaad.2023.04.034.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1900_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/bjd.18983","volume":"184","author":"AV Marzano","year":"2021","unstructured":"Marzano AV, Genovese G, Casazza G, et al. Evidence for a \u201cwindow of opportunity\u201d in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study. Br J Dermatol. 2021;184(1):133\u201340. https:\/\/doi.org\/10.1111\/bjd.18983.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1900_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ad.2022.12.005","volume":"115","author":"FJ Melgosa Ramos","year":"2024","unstructured":"Melgosa Ramos FJ, Garc\u00eda-Ruiz R, Mateu Puchades A, Martorell A. Can we improve prognosis in hidradenitis suppurativa? Identifying patients in the window of opportunity. Actas Dermosifiliogr. 2024;115(2):213\u20134. https:\/\/doi.org\/10.1016\/j.ad.2022.12.005. (in English and Spanish).","journal-title":"Actas Dermosifiliogr"},{"key":"1900_CR24","unstructured":"Vilarrasa E, Patricia G, Emili M, et al. Defining the window of opportunity in hidradenitis: unraveling predictors of sustained clinical remission (encore). Abstract No: 4742. EADV Congress, 25\u201328 September, 2024, Amsterdam. https:\/\/eadv.org\/scientific\/abstract-books\/. Accessed 26 Dec 2025."},{"issue":"4","key":"1900_CR25","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.clindermatol.2025.05.015","volume":"43","author":"T Tzellos","year":"2025","unstructured":"Tzellos T. Conventional treatment of hidradenitis suppurativa: serving the \u201cwindow of opportunity\u201d concept. Clin Dermatol. 2025;43(4):485\u20139. https:\/\/doi.org\/10.1016\/j.clindermatol.2025.05.015.","journal-title":"Clin Dermatol"},{"issue":"2","key":"1900_CR26","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/ijd.16889","volume":"63","author":"M Schultheis","year":"2024","unstructured":"Schultheis M, Grabbe S, Staubach P, et al. Drivers of disease severity and burden of hidradenitis suppurativa: a cross-sectional analysis on 553 German patients. Int J Dermatol. 2024;63(2):188\u201395. https:\/\/doi.org\/10.1111\/ijd.16889.","journal-title":"Int J Dermatol"},{"issue":"Suppl. 1","key":"1900_CR27","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/exd.14898ed","volume":"32","author":"E Vilarrasa","year":"2023","unstructured":"Vilarrasa E, Vidal S, Bittencourt F, Puig L, Gich I. Speed of progression: a new clinical parameter for therapeutic decision making in hidradenitis suppurativa. Exp Dermatol. 2023;32(Suppl. 1):104\u20135. https:\/\/doi.org\/10.1111\/exd.14898ed.","journal-title":"Exp Dermatol"},{"issue":"6","key":"1900_CR28","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/jid.2012.472","volume":"133","author":"F Canoui-Poitrine","year":"2013","unstructured":"Canoui-Poitrine F, Le Thuaut A, Revuz JE, et al. Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study. J Invest Dermatol. 2013;133(6):1506\u201311. https:\/\/doi.org\/10.1038\/jid.2012.472.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"1900_CR29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1159\/000511045","volume":"237","author":"A Gonz\u00e1lez-Manso","year":"2021","unstructured":"Gonz\u00e1lez-Manso A, Agut-Busquet E, Roman\u00ed J, et al. Hidradenitis suppurativa: proposal of classification in two endotypes with two-step cluster analysis. Dermatology (Basel). 2021;237(3):365\u201371. https:\/\/doi.org\/10.1159\/000511045.","journal-title":"Dermatology (Basel)"},{"issue":"6","key":"1900_CR30","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1111\/jdv.16183","volume":"34","author":"A Martorell","year":"2020","unstructured":"Martorell A, Jfri A, Koster SBL, et al. Defining hidradenitis suppurativa phenotypes based on the elementary lesion pattern: results of a prospective study. J Eur Acad Dermatol Venereol. 2020;34(6):1309\u201318. https:\/\/doi.org\/10.1111\/jdv.16183.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1900_CR31","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/bjd.15748","volume":"177","author":"CC Zouboulis","year":"2017","unstructured":"Zouboulis CC, Tzellos T, Kyrgidis A, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017;177(5):1401\u20139. https:\/\/doi.org\/10.1111\/bjd.15748.","journal-title":"Br J Dermatol"},{"issue":"8","key":"1900_CR32","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s40273-017-0488-2","volume":"35","author":"P Tappenden","year":"2017","unstructured":"Tappenden P, Carroll C, Stevens JW, et al. Adalimumab for treating moderate-to-severe hidradenitis suppurativa: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2017;35(8):805\u201315.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"1900_CR33","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1111\/bjd.17919","volume":"181","author":"GBE Jemec","year":"2019","unstructured":"Jemec GBE, Okun MM, Forman SB, et al. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials. Br J Dermatol. 2019;181(5):967\u201375. https:\/\/doi.org\/10.1111\/bjd.17919.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1900_CR34","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2018.05.040","volume":"80","author":"CC Zouboulis","year":"2019","unstructured":"Zouboulis CC, Okun MM, Prens EP, et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa\/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol. 2019;80(1):60-69.e2. https:\/\/doi.org\/10.1016\/j.jaad.2018.05.040.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"1900_CR35","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/j.1468-3083.2011.04065.x","volume":"25","author":"L Puig","year":"2011","unstructured":"Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol. 2011;25(9):1007\u201311. https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04065.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1900_CR36","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.jaad.2019.12.044","volume":"82","author":"JW Frew","year":"2020","unstructured":"Frew JW, Jiang CS, Singh N, et al. Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: a post hoc analysis of PIONEER 1 and 2 individual patient data. J Am Acad Dermatol. 2020;82(5):1150\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2019.12.044.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1900_CR37","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/ced.14448","volume":"46","author":"JW Frew","year":"2021","unstructured":"Frew JW, Jiang CS, Singh N, et al. Dermal tunnels influence time to clinical response and family history influences time to loss of clinical response in patients with hidradenitis suppurativa treated with adalimumab. Clin Exp Dermatol. 2021;46(2):306\u201313. https:\/\/doi.org\/10.1111\/ced.14448.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"1900_CR38","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/bjd.19863","volume":"185","author":"LM Prens","year":"2021","unstructured":"Prens LM, Bouwman K, Aarts P, et al. Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study. Br J Dermatol. 2021;185(1):177\u201384. https:\/\/doi.org\/10.1111\/bjd.19863.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1900_CR39","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1093\/bjd\/ljad530","volume":"190","author":"R Kj\u00e6rsgaard Andersen","year":"2024","unstructured":"Kj\u00e6rsgaard Andersen R, Pedersen O, Eidsmo L, Jemec G, Saunte D. Initial steps towards developing a predictive algorithm of disease progression for hidradenitis suppurativa (HS): results from a Cox proportional hazard regression analysis on disease progression among a cohort of 335 Danish patients with HS. Br J Dermatol. 2024;190(6):904\u201314. https:\/\/doi.org\/10.1093\/bjd\/ljad530.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1900_CR40","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/bjd.13090","volume":"171","author":"CB Kromann","year":"2014","unstructured":"Kromann CB, Deckers IE, Esmann S, Boer J, Prens EP, Jemec GB. Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study. Br J Dermatol. 2014;171(4):819\u201324. https:\/\/doi.org\/10.1111\/bjd.13090.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1900_CR41","doi-asserted-by":"publisher","first-page":"T56","DOI":"10.1016\/j.ad.2023.10.019","volume":"115","author":"E Vilarrasa","year":"2024","unstructured":"Vilarrasa E, Nicolau J, de la Cueva P, et al. [Translated article] Glucagon-like peptide-1 agonists for treating obesity in patients with immune-mediated skin diseases. Actas Dermosifiliogr. 2024;115(1):T56\u201365. https:\/\/doi.org\/10.1016\/j.ad.2023.10.019. (in English and Spanish).","journal-title":"Actas Dermosifiliogr"},{"issue":"8","key":"1900_CR42","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1111\/jdv.20550","volume":"39","author":"JR Ingram","year":"2025","unstructured":"Ingram JR, Marzano AV, Prens E, et al. Hidradenitis suppurativa with and without draining tunnels: a real-world study characterizing differences in treatment and disease burden. J Eur Acad Dermatol Venereol. 2025;39(8):1431\u201341. https:\/\/doi.org\/10.1111\/jdv.20550.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1900_CR43","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/bjd.19165","volume":"184","author":"CC Zouboulis","year":"2021","unstructured":"Zouboulis CC. First real-world data provide evidence for a \u201cwindow of opportunity\u201d in treatment of hidradenitis suppurativa\/acne inversa. Br J Dermatol. 2021;184(1):10\u20131. https:\/\/doi.org\/10.1111\/bjd.19165.","journal-title":"Br J Dermatol"},{"issue":"8","key":"1900_CR44","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.jid.2021.01.023","volume":"141","author":"G Vellaichamy","year":"2021","unstructured":"Vellaichamy G, Dimitrion P, Zhou L, et al. Insights from \u03b3-secretase: functional genetics of hidradenitis suppurativa. J Invest Dermatol. 2021;141(8):1888\u201396. https:\/\/doi.org\/10.1016\/j.jid.2021.01.023.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"1900_CR45","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.abd.2021.12.004","volume":"97","author":"JM Neves","year":"2022","unstructured":"Neves JM, Cunha N, Lencastre A, Cabete J. Treating hidradenitis suppurativa patients with adalimumab: a real-life experience of a tertiary care center in Lisboa, Portugal. An Bras Dermatol. 2022;97(6):816\u20139. https:\/\/doi.org\/10.1016\/j.abd.2021.12.004.","journal-title":"An Bras Dermatol"},{"issue":"1","key":"1900_CR46","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/ijd.13798","volume":"57","author":"VK Shanmugam","year":"2018","unstructured":"Shanmugam VK, Mulani S, McNish S, Harris S, Buescher T, Amdur R. Longitudinal observational study of hidradenitis suppurativa: impact of surgical intervention with adjunctive biologic therapy. Int J Dermatol. 2018;57(1):62\u20139. https:\/\/doi.org\/10.1111\/ijd.13798.","journal-title":"Int J Dermatol"},{"issue":"6","key":"1900_CR47","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.ad.2024.10.061","volume":"116","author":"L Mateu-Arrom","year":"2025","unstructured":"Mateu-Arrom L, Puig L, Vilarrasa E. Surgical approach to hidradenitis suppurativa. Actas Dermosifiliogr. 2025;116(6):621\u20137. https:\/\/doi.org\/10.1016\/j.ad.2024.10.061. (in English and Spanish).","journal-title":"Actas Dermosifiliogr"},{"issue":"11","key":"1900_CR48","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1111\/jdv.15710","volume":"33","author":"A Martorell","year":"2019","unstructured":"Martorell A, Alfageme Rold\u00e1n F, Vilarrasa Rull E, et al. Ultrasound as a diagnostic and management tool in hidradenitis suppurativa patients: a multicentre study. J Eur Acad Dermatol Venereol. 2019;33(11):2137\u201342. https:\/\/doi.org\/10.1111\/jdv.15710.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1900_CR49","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2026.1002","author":"RK Andersen","year":"2026","unstructured":"Andersen RK, Larsen MK, Ellervik C. Interpreting community-based remission and progression rates in hidradenitis suppurativa-reply. JAMA Dermatol. 2026. https:\/\/doi.org\/10.1001\/jamadermatol.2026.1002.","journal-title":"JAMA Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01900-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01900-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01900-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:00:34Z","timestamp":1791446434000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01900-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1900"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01900-0","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"30 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Eva Vilarrasa has received honoraria and\/or travel grants and\/or has served as an advisory board member and\/or has participated in clinical trials sponsored by Abbvie, Aceleryn, Almirall, Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Gebro, Incyte, Isdin, Janssen, Leo-Pharma, Lilly, Merck-Serono, MoonLake, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi, and UCB. She also has worked as consultant or participated in clinical trials for iDermApp, Mediktor, DermUS, Biomi, HSCalc, BHH. She is Secretary of the Spanish Group of Hidradenitis Suppurativa. Eva Vilarrasa is an Editorial Board member of\n                      Dermatology and Therapy\n                      . Eva Vilarrasa was not involved in the selection of peer reviewers for this manuscript nor in any of the subsequent editorial decisions. Patricia Garbayo-Salmons declares honoraria for participating in advisory boards from Novartis; has received speaker\u2019s honoraria and\/or travel support for attending meetings sponsored by Abbie, Amgen, Lilly, LEO Pharma, Novartis, and UCB. Emili Masferrer has received honoraria and\/or travel grants and\/or has served as an advisory board member for Almirall, Isdin, Galderma, Janssen, and Novartis; and has also worked as consultant or participated in clinical trials for IHT. Oriol Corral (ORCID number: 0000-0002-6001-9120) has received honoraria and\/or travel grants and\/or has participated in clinical trials sponsored by Abbvie, Almirall, Amgen, Celgene, Cantabria labs, Janssen, Leo-Pharma, Lilly, Novartis, Roche, Sandoz, Sanofi, and UCB. Veronica Mora (ORCID number: 0000-0003-0016-9781) has received honoraria for participation in advisory boards, in clinical trials, and\/or as a speaker; and has received travel grants from AbbVie Inc., Janssen, Johnson & Johnson, Novartis Pharma, Sanofi, and UCB Pharma. Julio Bassas-Vila has received honoraria and\/or travel grants and\/or has served as an advisory board member and\/or has participated in clinical trials sponsored by Abbvie, Almirall, Moonlake, Incyte, Isdin, UCB, and Novartis. Mar Luque reports no conflicts of interest. Irene Fuertes reports no conflicts of interest. Rosa Fornons-Servent has received honoraria and\/or travel grants and\/or has served as an advisory board member and\/or has participated in clinical trials sponsored by AbbVie, Almirall, Bristol-Myers Squibb, Cantabria, Ferrer, Isdin, Galderma, Janssen, Johnson&Johnson, Leo Pharma, Lilly, Novartis, Roche, Sanofi, and UCB. Gemma Martin-Ezquerra has received honoraria and\/or travel grants and\/or has served as an advisory board member and\/or has participated in clinical trials sponsored by Boehringer Ingelheim, MoonLake, Novartis, UCB. Rafael S. Aguayo-Ortiz (ORCID number: 0000-0002-1690-1618) has received honoraria and\/or travel grants from Abbvie, Novartis, Janssen, and Lilly. Joan Ceravalls reports no conflicts of interest. \u00c1lvaro G\u00f3mez has received honoraria and\/or travel grants and\/or has served as an advisory board member and\/or has participated in clinical trials sponsored by Abbvie, Almirall, Galderma, Janssen, Legit-Health, Leo-Pharma, Lilly, MSD, Novartis, Sanofi, and UCB. Jordi Mollet has received honoraria and\/or has served as an advisory board member and\/or has participated in clinical trials sponsored by Abbvie, Almirall, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Janssen, Leo-Pharma, Lilly, Novartis, Pfizer, Sanofi, and UCB. Clara Matas reports no conflicts of interest. Ignasi Gich reports no conflicts of interest. Jorge Roman\u00ed has received honoraria and\/or travel grants and\/or has served as an advisory board member and\/or has participated in clinical trials sponsored by Abbvie, Almirall, Moonlake, Boehringer Ingelheim, Incyte, Isdin, UCB, S-Biomedic, Biersdorf, and Novartis.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol received approval from the Ethics Committee of Hospital Parc Taul\u00ed (Protocol number 2022\/5109), which waived the requirement for informed consent to conduct the study due to the retrospective nature of data collection from routine practice records. This investigation complied with Good Clinical Practice standards and the International Council for Harmonization directives, as well as with the ethical principles outlined in the Declaration of Helsinki. Additionally, all pertinent national regulations governing clinical research were observed, with precedence given to those affording the highest level of protection to individual participants. To safeguard participant confidentiality, all personally identifiable data were either encrypted or expunged.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}